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ABSTRACT 
Oxymorphone, one of oxycodone’s metabolic products, is a potent opioid receptor 
agonist which is thought to contribute to the analgesic effect of its parent compound 
and may have high potential abuse liability. Nonetheless, the in vivo pharmacological 
binding profile of this drug is still unclear. This study uses mice lacking mu (MOP), 
kappa (KOP) or delta (DOP) opioid receptors as well as mice lacking all three opioid 
receptors to provide full characterisation of oxymorphone binding sites in the brain. 
Saturation binding studies using [3H]oxymorphone revealed high affinity binding sites 
in mouse brain displaying Kd of 1.7 nM and Bmax of 147 fmol/mg.  Furthermore, we 
performed quantitative autoradiography binding studies using [3H]oxymorphone in 
mouse brain.  The distribution of [3H]oxymorphone binding sites was found to be similar 
to the selective MOP agonist [3H]DAMGO in the mouse brain.  [3H]Oxymorphone 
binding was completely abolished across the majority of the brain regions in mice 
lacking MOP as well as in mice lacking all three opioid receptors. DOP and KOP 
knockout mice retained [3H]oxymorphone binding sites suggesting oxymorphone may 
not target DOP or KOP. These results confirm that the MOP, and not the DOP or the 
KOP is the main high affinity binding target for oxymorphone.   
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1. Introduction 
Oxycodone is widely used opioid medication in the US [16].  Oxymorphone, an 
active metabolite of oxycodone through O-demethylation, is a potent opioid agonist 
[18].  Oxycodone’s pharmacodynamic effects in humans and other mammalian species 
were shown to be produced by the parent drug, rather than its metabolite oxymorphone 
[13, 14].  Despite its low metabolism to oxymorphone, oxymorphone may still 
contribute towards the pharmacological effects of its parent compound depending on 
its pharmacological potency.  
There is evidence suggesting that oxycodone and oxymorphone activates 
distinct molecular pathways [1, 29].  For instance, oxycodone is 10- to 100-fold less 
potent than oxymorphone in activating intracellular G-proteins (agonist-stimulated 
GTPγ[35S] binding assay) in several CNS regions of rats [20]. In addition, 
oxymorphone-induced antinociceptive effects were blocked by naloxone in rats [20] 
and abolished in mice lacking mu opioid (MOP) receptors [32] whereas oxycodone-
mediated antinociception could be attenuated by blocking kappa (KOP) or delta opioid 
(DOP) receptors in rats [24] and mice [32], respectively. Furthermore, intrathecal 
administration of oxymorphone produced longer and significantly greater 
antinociception compared to oxycodone in rats [20].  Altogether, these studies indicate 
that although oxymorphone is not the main metabolite of oxycodone, it may contribute 
to its analgesic effect due to its higher potency to cause MOP desensitisation and G- 
protein activation in the CNS.  
Oxymorphone is effective for the relief of moderate and severe pain [12, 15].  
Oxymorphone displayed 320- to 410-fold higher affinity for human MOP expressing 
CHO-K1 cells (Ki = 0.36 nM) than for the human KOP (Ki = 148 nM) or mouse DOP (Ki 
= 118 nM) expressing cells [18]. However, there is some evidence that oxymorphone 
can also interact with the DOP. For instance oxymorphone was able to competitively 
displace the DOP selective ligand [3H]DADLE binding at its high affinity binding site 
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but had a non-competitive effect at a lower affinity binding site in the rat brain [25], thus 
proposing binding activity of oxymorphone with putative DOP subtypes.  
To further provide the full characterization of receptor binding profile of 
oxymorphone in vivo, we synthesised [3H]oxymorphone  and carried out saturation 
binding studies in mouse brain homogenates. We performed detailed quantitative 
[3H]oxymorphone autoradiographic receptor mapping in brains of mice lacking either 
MOP, KOP or the DOP as well as in mice lacking all three classical opioid receptors 
(MOP/KOP/DOP) in order to fully characterise the oxymorphone opioid receptor 
binding sites in vivo. This is the first complete autoradiographic mapping study using 
[3H]oxymorphone to directly and fully characterise oxymorphone  binding sites.  The 
results suggest that the MOP and not DOPs or KOPs is the main binding target of 
oxymorphone throughout the brain tissue.   
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2. Material and methods 
 
2.1. Animals. Mice lacking MOP, DOP or KOP (congenic C57BL/6 mice) and 
appropriate wild-type (WT) controls were derived following at least 10 generations of 
successive backcrossing of 129/SV × C57BL/6 heterozygotes to C57BL/6 [9, 21, 27].  
Triple mutant mice lacking MOP, DOP and KOP genes and wild-type (WT) mice were 
generated by interbreeding of congenic C57BL/6 MOP [21], DOP [9], and KOP [27] 
knockout (KO) mice [26], maintained on a pure C57BL/6 genetic background. Animals 
used in this study were > 8 weeks old adult male and female mice and were genotyped 
by PCR at weaning. Membrane fractions were prepared from brains of C57BL/6 mice 
(2 months old).   All housing and experimental procedures were carried out in 
accordance with the European Communities Council Directive of 24 November 1986 
and the Hungarian legislation for the Protection of Animals in Research (XXVIII.tv. 
Section 32.).  
. 
2.2. Materials. [3H]Oxymorphone (34 Ci/mmol) was synthesised at the Institute of 
Biochemistry, Biological Research Centre of the Hungarian Academy of Sciences.  
Naloxone was purchased from Sigma-Aldrich (Sigma-Aldrich Company Ltd., Dorset, 
UK).  
 
2.3. Homogenate binding studies. Freshly dissected whole brains excluding 
cerebellum of mice were homogenized in ice-cold 50 mM Tris-HCl buffer solution (pH 
7.4, 1 g wet weight/10 mL) with an electrically driven Braun teflon-glass rota-machine.  
The crude homogenate was centrifuged at 40,000g, 4C, for 20 min.  Pellets were 
resuspended in the same volume of fresh 50 mM Tris-HCl pH 7.4 buffer and 
centrifuged again as above.  The final pellet was taken up and homogenized with buffer 
and used immediately in the binding assays.  Radioligand binding studies were 
conducted in 50 mM Tris-HCl buffer in a final volume of 1 mL.  Mouse brain 
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homogenates were incubated in the presence of the [3H]oxymorphone at a range of 
different concentrations (0.16 nM – 32 nM) for 30 min at 24C. The incubation time 
was chosen based on time course binding studies (Fig. 1A). Association kinetics was 
performed by incubating the samples for different times as indicated in the Fig. 1A.  
Reaction mixtures were filtered together to determine bound radioactivity.  The reaction 
was terminated and bound and free radioligands were separated by rapid filtration 
under vacuum through Whatman GF/C glass fiber filters using a Brandel M24R Cell 
Harvester.  Filters were dried, then immersed into UltimaGold™ (Packard) solution. 
Bound radioactivity was determined by a Packard TriCarb 2300TR Liquid Scintillation 
Analyzer. Saturation binding studies were carried out by incubating the samples in the 
presence of increasing concentrations of the radioligand (Fig. 1B).  Non-specific 
binding (NSB) was measured in the presence of 10 M naloxone.  NSB was subtracted 
from total [3H]oxymorphone binding to determine equilibrium specific binding for 
calculation of  Kd and Bmax. Equilibrium competition studies were performed by 
incubating the samples in the presence of 2 nM radioligand and increasing 
concentration of unlabelled naloxone.   
 
2.4. Preparation of knockout tissue for sectioning. Single MOP, DOP and KOP KO 
mice and triple opioid receptor KO mice and their respective WT controls were killed 
and the brains were immediately removed and snap frozen at -20 °C in isopentane. 
Frozen brains were removed from storage in a -80 °C freezer and were placed into a 
Cryostat (Zeiss Microm HM505E, Jena, Germany), and equilibrated at -20 °C.  20 μm 
coronal (300 μm apart) or sagittal sections from the brains of opioid receptor KO and 
WT mice, were then cut and thaw-mounted onto gelatine coated ice-cold slides to 
assess levels of binding from fore- to hind-brain regions. Consecutive sections were 
taken for determination of total and non-specific binding. 
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  2.5. Quantitative [3H]oxymorphone Autoradiographic binding. Autoradiographic 
binding was carried out according to the general principles described by our group [17, 
33].  All sections were preincubated in 50 mM Tris-HCl, pH 7.4, plus 0.9 % NaCl for 30 
min at room temperature, to remove endogenous opioids. Sections were then 
incubated with 5 nM (3x Kd) [3H]oxymorphone in 50 mM Tris-HCl, pH 7.4, for 60 min at 
room temperature for total binding.  Adjacent section slides were incubated with 
[3H]oxymorphone (5nM) in the presence of 10 μM naloxone to determine non-specific 
binding. Slides were washed 3 times with ice-cold Tris-HCl buffer, pH 7.4, for 5 min 
and rapidly cool-air dried.  
Autoradiograms were generated by apposing the labelled tissues to Kodak 
BioMax MR films (Eastman Kodak Co., Rochester, NY, USA).  Cassettes were sealed 
using opaque tape to prevent light entry and stored in a dark place for a period of 7 to 
9 weeks in X-ray film cassettes along with Amersham tritiated polymer standards at 
room temperature.  Kodak BioMax MR films were developed in 50 % Kodak D19 
developer solution (Eastman Kodak Co., Rochester, NY, USA) and fixed with Kodak 
Rapid fixer (Eastman Kodak Co., Rochester, NY, USA). Sections from WT and KO 
animals were processed together to ensure a paired protocol for binding, film 
apposition and image analysis. 
All films were analysed by video-based computerized densitometry using an 
MCID image analyser (Imaging Research, St. Catharines, ON, Canada) as previously 
described [17, 33]. Structures were identified by reference to the mouse atlas of 
Franklin & Paxinos [10].  Specific binding was calculated by subtracting the level of 
non-specific binding from the total binding level. 
 
2.6. Data analysis. For autoradiographic studies, statistical analysis was performed 
by one-way ANOVA for each brain region, followed by Dunnett’s post hoc test to 
compare all the other group to the WT. The data from competition and saturation 
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binding studies were analyzed and graphically processed by GraphPad Prism (San 
Diego, CA, USA). 
 
3. Results 
3.1. Binding of [3H]oxymorphone to brain homogenates.  Radioligand binding 
studies revealed the presence of specific, high affinity binding sites for 
[3H]oxymorphone in mouse brain homogenates (Fig. 1, Table 1).  Binding of 
[3H]oxymorphone to mouse brain membranes at 24C was saturable and of high affinity 
(Fig. 1A). [3H]Oxymorphone displayed binding to mouse brain membranes with a Kd 
of 1.7 nM and Bmax of 147 fmol/mg (Fig. 1B, Table 1).  The universal opioid antagonist, 
naloxone displaced [3H]oxymorphone  with  a Ki value of 1.8 nM (Fig. 1C, Table 1).  
 
3.2. [3H]oxymorphone binding in wild-type, MOP, KOP and DOP receptor 
knockout mice.  At a near saturating concentration (5nM, 3-4 x Kd) (Table 1), high 
levels (>28 fmol/mg) of [3H]oxymorphone binding were detected in the nucleus 
accumbens, thalamus, hypothalamus, medial habenular nucleus, superficial gray layer 
of the superior colliculus and periaqueductal gray of WT mice (Fig. 2 and Table 2).  
The qualitative pattern of [3H]oxymorphone binding in WT mice was similar to that of 
DOP and KOP KO mice (Fig. 2 and Table 2).  One-way ANOVA revealed a significant 
genotype effect in the nucleus accumbens core (P < 0.01) and shell (P < 0.01), caudate 
putamen (P < 0.01), cingulate cortex (P < 0.05), secondary motor cortex (P < 0.05), 
primary motor cortex (P < 0.01), hippocampus (P < 0.001), thalamus (P < 0.001), 
hypothalamus (P < 0.001), amygdala (P < 0.001), medial habenular nucleus (P < 
0.001), superficial gray layer of the superior colliculus (P < 0.001), periaqueductal gray 
(P < 0.001), substantia nigra (P < 0.001) and ventral tegmental area (P < 0.001).  
[3H]Oxymorphone binding was almost completely abolished in the majority of the brain 
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regions analysed in MOP KO mice vs WT (83% mean decrease in binding vs WT brain 
across all regions) (Table 2). Unlike the case for MOP receptor KO mice, 
[3H]oxymorphone binding was completely retained at WT levels in DOP and KOP KO 
mice across all regions. No significant differences in [3H]oxymorphone binding was 
detected in WT vs KOP KO and DOP KO groups in any regions with the exception of 
the hippocampus where higher levels of binding was observed in KOP KO (78% 
increase vs WT, P<0.05) (Table 2).  
 
3.3. [3H]oxymorphone binding in triple opioid receptor knockout mice.  Triple 
opioid receptor KO mice were used to determine whether the ligand bind to non-opioid 
receptors.  No [3H]oxymorphone binding was detected in brains of mice lacking all 
three classical opioid receptors (triple KO mice) (Fig. 3). 
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4. Discussion 
In the present study, we showed that the anatomical distribution of oxymorphone 
in mouse brain was similar to the MOP agonist [3H]DAMGO. To further investigate whether 
oxymorphone interacts to any other opioid receptor and/or non-opioid binding sites, we 
characterise the pharmacological binding profile of [3H]oxymorphone in mice lacking MOP, 
KOP and DOP receptor as well as in the mice lacking all three classical opioid receptor 
genes. No specific [3H]oxymorphone binding was detected in the mice lacking MOP and 
three classical opioid receptor genes, whereas binding remained mostly unchanged in 
brains of KOP and DOP knockout mice, indicating a lack of interaction of the ligand with 
any other sites apart from the classical opioid receptor binding sites. Thus oxymorphone 
binds specifically to high affinity MOP sites but not to the KOP or the DOP. 
The distribution of [3H]oxymorphone binding in the brains of WT mice was found to 
be similar to that of MOP receptor binding as labelled with the selective MOP receptor 
agonist  [3H]DAMGO in the mouse brain [17].  High levels of [3H]oxymorphone binding was 
detected in the nucleus accumbens, thalamus, hypothalamus, medial habenular nucleus, 
superficial gray layer of the superior colliculus and the periaqueductal gray which are all 
regions of high MOP receptor expression [17].  Moderate binding levels of 
[3H]oxymorphone were detected in the olfactory tubercle, caudate putamen, amygdala and 
substantia nigra which is in complete accordance with the presence of moderate MOP 
receptor expression as observed by Kitchen et al. [17] with the use of [3H]DAMGO.  Finally, 
low levels of [3H]oxymorphone binding were found in the prelimbic cortex, frontal 
association cortex, cingulate cortex, secondary motor cortex, primary motor cortex and 
hippocampus which are regions of low MOP receptor binding [3, 4, 17].   
To further demonstrate whether MOP receptor is the prime target for oxymorphone, 
[3H]oxymorphone autoradiographic binding was carried out in the brains of mice lacking 
the MOP receptor.  There was almost complete abolition of [3H]oxymorphone binding in 
the majority of the brain regions of MOP receptor KO mice, demonstrating that MOP 
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receptor is the main binding target for oxymorphone in mouse brain tissue.  In support of 
this evidence, a competition binding  study in a cell membrane preparation expressing 
recombinant human MOP receptor showed oxymorphone has a high affinity to the MOP 
receptor (Ki = 0.4055 nM) [30].  Moreover, in agreement with the present study, 
oxymorphone had relatively high affinity for human MOP receptor expressing CHO-K1 
cells (Ki = 0.36 nM), but 410-fold lower for the human KOP (Ki = 148 nM) and 320-fold 
lower for mouse DOP (Ki = 118 nM) expressing cells than the human MOP receptor 
expressing CHO cells [18]. 
Despite the substantial loss of [3H]oxymorphone binding sites in MOP receptor KO 
mice, [3H]oxymorphone binding was retained in DOP and KOP KO mice demonstrating a 
lack of binding interaction of oxymorphone to DOP or KOP.  In support of this evidence, 
oxymorphone-induced antinociception in both thermal and mechanical tests in rats was 
not reversed by the KOP selective antagonist norbinaltorphimine suggesting that 
oxymorphone-induced antinociception is not mediated by the KOP [20].  The present study, 
however, with the use of MOP, KOP and DOP receptor KO mice provides definitive 
evidence that the prime binding site of oxymorphone in mouse brain is the MOP receptor 
and not the DOP or KOP receptor.  Results from our study show that oxymorphone binds 
almost exclusively to MOP in brain regions involved in pain modulation (thalamus, 
periaqueductal grey), reward (VTA, nucleus accumbens, caudate putamen) and 
emotionality (amygdala, hippocampus, cingulated cortex, hypothalamus).  Oxycodone is 
partly metabolized to oxymorphone via O-methylation and is mainly metabolized to 
noroxycodone via N-demethylation in humans [19, 31].  It is still an open question whether 
oxymorphone’s MOP activity contributes greatly to the action of oxycodone. Recently, 
Babalonis et al. [2] accessed the abuse potential of oxymorphone and oxycodone in 
healthy non-physically dependent opioid abusers and showed that the high dose of 
oxymorphone (40 mg/kg) increased the ratings of drug linking as being similar to 
oxycodone.  These certainly explain the potent analgesic effect and the potential abuse 
liability of oxymorphone itself [6] but may be also of its parent compound oxycodone. 
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Indeed the abuse of oxycodone containing analgesics has increased among drug abusers 
[7].   
Interestingly, a significantly higher level of [3H]oxymorphone binding was observed 
in the hippocampus of KOP KO mice compared to WT animals.  As we established that 
[3H]oxymorphone binds to MOP and not the KOP or DOP with high affinity, one possible 
explanation is that this increase may reflect increase of the MOP in the hippocampus of 
KOP KO.  This is unlikely to be the case as autoradiographic binding of MOP with 
[3H]DAMGO in the brains of KOP KO mice did not show any compensatory alterations of 
MOP sites in the brain [28].  Another possibility explaining higher levels of 
[3H]oxymorphone binding in the hippocampus of KOP KO mice is the absence of low 
affinity KOP-MOP dimers which would be present in WT mice. As a result, the proportion 
of MOP/MOP-KOP+MOP would be higher in the KOP KO mice vs WT.  As oxymorphone 
binds to high affinity MOP, this may explain the higher oxymorphone binding in the 
hippocampus of KOP KO mice. Although it is not yet known whether opioid receptors exist 
as dimers, which may be present as homo- or heterodimers/oligomers in physiological 
systems [5, 8, 11, 22, 23], various studies have suggested that some opioid receptor 
agonists or antagonists might be able to distinguish monomer and heterodimers in 
physiological systems, in vivo and in vitro.  
In conclusion, these results indicate that the MOP, and not the DOP or the KOP is 
the main high affinity binding target for oxymorphone. This suggests that the 
pharmacological effect of oxymorphone is most likely to be mediated via a MOP dependent 
mechanism.  
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Figure legends 
 
Fig. 1. Binding properties of [3H]oxymorphone in mouse brain homogenates time course 
association kinetics (A), saturation binding curve (B), equilibrium competition (C). Time-
dependence of binding interaction was examined by incubating the mouse brain 
membrane preparations with 2 nM [3H]oxymorphone at various time points (A). For 
saturation binding, mouse brain membranes (0.2 mg protein, 1 mL volume) were 
incubated with increasing concentration of 0.16 - 32 nM [3H]oxymorphone in the presence  
and absence of 10 µM naloxone for 30 min at 24 C (B). For competition binding studies, 
mouse brain membranes were incubated with 2 nM [3H]oxymorphone in the presence of 
increasing concentration of naloxone 10-12 – 10-5 M (C). The symbols in the graph represent 
mean ± SEM of three independent determinations performed in duplicates.  
 
Fig. 2. Representative pseudo-colour images showing [3H]oxymorphone (5 nM) binding in 
the brains of wild-type, MOP, KOP and DOP opioid receptor  knockout (KO) mice.  Images 
were taken at bregma level +2.8mm (prelimbic cortex and frontal association cortex), 
+1.1mm (nucleus accumbens core and shell, olfactory tubercle, caudate putamen, 
cingulate cortex, secondary motor cortex and primary motor cortex), -1.9mm 
(hippocampus, thalamus, hypothalamus, amygdala and medial habenular nucleus) and -
3.6mm (superficial gray layer of the superior colliculus, periaqueductal gray, substantia 
nigra and ventral tegmental area).  Non-specific binding (NSB) was determined in the 
presence of 10 μM of naloxone.  The colour bar represents pseudo-colour interpretation of 
black and white film images in fmol/mg tissue. 
 
Fig. 3.  Representative pseudo-colour images showing [3H]oxymorphone (5 nM) in sagittal 
brain sections of wild-type and all three classical opioid receptor (MOP/KOP/DOP) 
knockout (KO) mice. Non-specific binding (NSB) was determined in the presence of 10 μM 
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of naloxone.  The colour bar represents pseudo-colour interpretation of black and white 
film images in fmol/mg tissue.   
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Table 1. Binding parameters for oxymorphone in mouse brain homogenates 
Parameter [3H]oxymorphone 
Equilibrium dissociation constant1 Kd   (nM) 1.7  0.4    (3) 
Binding capacity1 Bmax  (fmol/mg protein) 147  16    (3) 
pIC50 2 8.3  0.09    (3) 
Equilibrium inhibition constant2,3 Ki   (nM) 1.8  
 
 
Legend to Table 1. 
Data are mean values  SEM, number of independent experiments are given in 
parenthesis. 
1) from equilibrium saturation binding studies 
2) from homologous competition studies  
3) calculated by the Cheng-Prusoff equation  
 
Table 2. 5 nM [3H]oxymorphone binding in MOP, KOP and DOP knockout mice. 
Region [3H]oxymorphone-specific binding (fmol/mg tissue)   
% Change in binding  
(vs. wild-type) 
  Wild-type   MOP KO KOP KO DOP KO   MOP KO KOP KO DOP KO 
Prelimbic cortex 17.9 
 
± 5.2 8.8 
 
± 1.8 20.5 
 
± 3.9 16.8 
 
± 4.0   
 
-51  
 
15  
 
-6  
Frontal association cortex 17.2 ± 3.9 8.4 ± 1.6 17.3 ± 4.0 11.4 ± 2.4   -51  1  -34  
Nucleus accumbens core 42.0 ± 12.3 6.1 ± 2.8 ** 44.6 ± 4.9 40.1 ± 6.9   -85  6  -5  
Nucleus accumbens Shell 38.2 ± 11.6 5.0 ± 2.5 * 47.3 ± 5.9 38.5 ± 7.8   -87  24  1  
Olfactory tubercle 24.5 ± 7.7 10.1 ± 2.9 22.8 ± 5.4 21.7 ± 3.8   -59  -7  -11  
Caudate putamen 25.3 ± 5.9 3.6 ± 2.3 * 23.6 ± 5.2 24.5 ± 4.1   -86  -7  -3  
Cingulate cortex 16.7 ± 4.0 2.4 ± 1.0 * 18.1 ± 4.7 15.1 ± 3.8   -86  9  -9  
Secondary motor cortex 16.2 ± 4.3 1.8 ± 1.1 * 14.1 ± 3.6 12.0 ± 2.7   -89  -13  -26  
Primary motor cortex 13.9 ± 3.1 1.0 ± 0.6 ** 12.1 ± 3.2 12.8 ± 2.3   -93  -12  -8  
Hippocampus 5.6 ± 0.7 1.8 ± 0.9 10.0 ± 1.0 * 4.7 ± 1.3   -68  78  -16  
Thalamus 28.2 ± 3.9 1.0 ± 0.5 *** 30.7 ± 2.7 25.8 ± 3.6   -97  9  -9  
Hypothalamus 29.7 ± 3.5 0.7 ± 0.3 *** 33.9 ± 1.6 28.7 ± 3.6   -98  14  -3  
Amygdala 24.1 ± 2.4 1.9 ± 0.6 *** 30.4 ± 2.7 28.7 ± 2.5   -92  26  19  
Medial habenular nucleus 43.7 ± 9.0 2.4 ± 2.0 *** 55.3 ± 5.2 55.0 ± 4.6   -95  27  26  
Superficial gray layer of the superior colliculus 41.4 ± 4.8 4.8 ± 2.8 *** 46.2 ± 2.2 38.4 ± 2.5   -88  12  -7  
Periaqueductal gray 31.5 ± 4.1 2.9 ± 0.8 *** 28.3 ± 3.5 28.8 ± 2.8   -91  -10  -9  
Substantia nigra 20.3 ± 5.2 0.6 ± 0.2 ** 22.1 ± 4.2 22.1 ± 2.6   -97  9  9  
Ventral tegmental area 22.4 ± 5.0 2.9 ± 0.7 ** 27.5 ± 4.7 28.5 ± 1.5   -87  23  27  
                 
 
  
 
 
 
 
 Legend to Table 2. 
Quantitative autoradiography of 5 nM [3H]oxymorphone binding in the brains of wild-type (WT), MOP, KOP and DOP knockout (KO) 
mice.  Values are expressed as mean ± SEM of 4 - 5 mice.  *P < 0.05, **P < 0.01 and ***P < 0.001 compared to WT mice (Dunnett's 
post hoc test).  The mean decreases in binding across all regions were 83 % and 4 % in MOP and DOP KO mice vs WT, respectively.  
The mean increase in binding across all regions was 11 % in KOP KO mice vs WT.  
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